Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
01/12/2025 13:39
Dec 1 (Reuters) - Lotus Pharmaceutical Co Ltd 1795.TW: LENZ THERAPEUTICS ANNOUNCES MFDS SUBMISSION OF NEW DRUG APPLICATION FOR LNZ100 (VIZZ™) IN SOUTH KOREA FOR THE TREATMENT OF PRESBYOPIA Source text: ID:nGNX5V5qyL Further company coverage: 1795.TW ((Reuters.Briefs@thomsonreuters.com;))